Fong, Khi Yung, Chan, Yiong Huak, Wang, Yue, Yeo, Colin, Rosario, Barbara Helen 
ORCID: 0000-0001-5491-3524, Lip, Gregory YH ORCID: 0000-0002-7566-1626 and Tan, Vern Hsen
(2023)
Dementia Risk of Direct Oral Anticoagulants Versus Warfarin for Atrial Fibrillation: Systematic Review and Meta-Analysis.
JACC. Asia, 3 (5).
pp. 776-786.
Abstract
<h4>Background</h4>Direct-acting oral anticoagulants (DOACs) have demonstrated superior efficacy in preventing stroke and death compared with warfarin in patients with atrial fibrillation (AF), but their influence on dementia risk remains unclear.<h4>Objectives</h4>The purpose of this study was to evaluate the relative risks of dementia in DOAC vs warfarin in patients with AF.<h4>Methods</h4>An electronic literature search was conducted to retrieve studies reporting comparisons of dementia incidence between patients treated with DOACs and warfarin for AF. HRs and 95% CI were pooled in a random-effects meta-analysis. Meta-regression was performed to identify prognostic baseline variables. Network meta-analysis was performed to determine dementia risk between individual DOACs and warfarin.<h4>Results</h4>Ten studies (n = 342,624) were retrieved. DOAC was associated with a significantly lower risk of developing dementia compared with warfarin (HR: 0.88; 95% CI: 0.80-0.98; <i>P</i> = 0.017; I<sup>2</sup> = 75%); significance was also seen in Asian patients (HR: 0.81; 95% CI: 0.68-0.86) but not non-Asian patients. Subgroup analyses of propensity score-matched studies and patients aged 65-75 years showed similar significance, but not for patients aged ≥75 years. Meta-regression found that a lower mean age corresponded to significantly greater favoring of DOAC over warfarin. Network meta-analysis found significant reductions in dementia risk over warfarin for rivaroxaban (HR: 0.854; 95% CI: 0.763-0.955), apixaban (HR: 0.881; 95% CI: 0.778-0.997), and dabigatran (HR: 0.871; 95% CI: 0.770-0.987); the highest-ranked treatment based on P scores was edoxaban.<h4>Conclusions</h4>The use of DOAC in AF significantly reduces dementia risk compared with warfarin, particularly in Asian patients. The possible reversal of this effect with increasing age merits further randomized trials with long-term follow-up. (Dementia Risk of Direct Oral Anticoagulants Versus Warfarin for Atrial Fibrillation: A Systematic Review and Meta-Analysis; CRD42022365634).
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | anticoagulants, atrial fibrillation, dementia, meta-analysis, warfarin |
| Divisions: | Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 06 Feb 2024 09:40 |
| Last Modified: | 06 Feb 2024 09:40 |
| DOI: | 10.1016/j.jacasi.2023.07.012 |
| Open Access URL: | https://doi.org/10.1016/j.jacasi.2023.07.012 |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3178406 |
Dimensions
Dimensions
